1 / 36

A.D’Hoore MD PhD , A. Wolthuis MD, F. Penninckx MD PhD

Organ sparing-strategy in rectal cancer Importance – How can we progress ?. A.D’Hoore MD PhD , A. Wolthuis MD, F. Penninckx MD PhD K. Haustermans MD PhD*, E. Van Cutsem MD PhD** V. Vandecaveye MD PhD*** Department of Abdominal Surgery, Radiation Oncology*, GI Oncology** and Radiology***

vivian-kirkland
Télécharger la présentation

A.D’Hoore MD PhD , A. Wolthuis MD, F. Penninckx MD PhD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Organ sparing-strategy in rectal cancer Importance – How can we progress ? A.D’HooreMD PhD, A. Wolthuis MD, F. Penninckx MD PhD K. Haustermans MD PhD*, E. Van Cutsem MD PhD** V. Vandecaveye MD PhD*** Department of Abdominal Surgery, Radiation Oncology*, GI Oncology** and Radiology*** Catholic University of Leuven Belgium

  2. Actualtreatment in rectalcancer Earlyrectalcancer (T1,T2,N0) Advancedrectalcancer ≥ T3, TxN1 Neoadjuvant (chemo)radiotherapy T1sm1 < 3 cm good-moderatedifferentiation absence LV-invasion non-ulcerated RadicalSurgery (TME +/- proctectomy) TEM/TAE

  3. Surgery is the mainmechanismforcure in colo-rectalcancer

  4. neo-adjuvantchemoradiation preferredstrategy to furtherimprovelocalcontrol Sauer R et al. N Engl J Med2004; 351:1731-40.

  5. Currentstrategy neoadjuvantchemoradiation radicalsurgery (TME) - risk for permanent stoma - deterioration of bowel function • increased risk surgicalcomplications • increased postop deathrate (elderly) • longterm impact anorectal/sexualfunction

  6. Appeal of organpreservation • Minimal perioperativemorbidity and mortality • - bleeding • - anastomoticleak • Rapidrecovery • Sphinctersavingoperation • Preservation of bowelfunction • - ‘anteriorresection’ syndrome • - permanent colostomy • Preservation of urogentialfunction • ImprovedQoL • Reduction in Health care cost

  7. Effect of neoadjuvantchemoradiation • - improvelocal tumor control • tumor downsizing • cancer,nodal sterilization : 12 – 24%

  8. Complete pathological response (pR) to neoadjuvantchemoradiotherapy

  9. n= 265 pts, distal rectalcancer 0S Local Excision: n = 22 pts (8.3%) pT0 stratification at 8-10 weeks ….observation __ radical surgery DFS wait and see n = 71 pts (26.8%) sustainedcCR Ann Surg 2004;240(4):711-7

  10. Late recurrences overall : 21% (n=15) Habr-Gama A et al. SeminRadiatOncol2011;21:234-239.

  11. Nodalmetastasis in relation to ypT

  12. male, 57 yr. uT1 , 2 cm aboveanalverge TAE : pT1 sm3, G2-3 LV+, PN – Adjuvantchemoradiation : 50.4 Gy, infusional 5 FU Intensive FU : 5 years yearlyendoscopy at 9 years: sciatic pain +++ Background risk foruntreatednodaldisease

  13. Actual series onnon-operativetreatmentafterchemoradiation and cCR

  14. “wait and seeprotocols” • lack of clarity to defineclinical complete response (cCR) • - clinical criteria • - imaging • - punch biopsy – TEM (excisionalbiopsy) • 20% fail the firstyear (earlyfailure) • - outcome early salvage • uncertainty in regard to long-termefficacy (late failure) • - rational, consistent follow-up programme • - selection of patients • - outcome late salvage

  15. Complete clinical response (Habr Gama)inter observer variablity ? • careful digital examination • proctoscopy • - whitening of mucosa • - teleangiectasia • - loss of plicability of rectalwall • Habr-Gama et al. Dis of Colon Rectum 2010;53:1692-1698

  16. Predictivevalue of clinical complete response (ccR) n= 488 patients MemorialSloanKettering ccR = 19% cpR = 10% ccR = predictive factor forcpR but : 75% of ccR : residual foci of tumor:

  17. Significance of residualmucosalabnormalities ? 61% (19/31) withcPR had anincomplete cR ypT0N0 ypT0N0 ypT3N1 ypT0N0 Smith FM et al. Br J Surg 2012; 99:993-1001

  18. Canbiopsiesrule out persistingcancerin incomplete clinical response ? PPV = 100% NPV = 21% accuracy = 71% Perez RO et al. Colorectal Dis 2012

  19. TransanalEndoscopicMicrosurgery (TEM) Buess G et al. SurgEndosc1988; 2: 245- 250

  20. Pooled data on TEM afterneo-adjuvant chemoradiotherapy 6 retrospective studies, 1 prospectivestudy Borschitz T et al. Ann SurgOncol2008;15:712-720

  21. Morbidity TEM afterneoadjuvantchemoradiationtherapy Perez RO et al. Dis Colon Rectum 2011; 54: 545-551

  22. Maastricht (Dutch) criteria formultimodal assessment of response • substantialdownsizing: noresidual tumor, onlyfibrosis • (low signalon high b-valueDW- MRI) • -nosuspiciouslymphnodesonMRI • (USPIO, gadofosveset) contrast enhanced MRI • -noresidual tumor at endoscopy (residualscar) • normalbiopsiesfrom the scar • nopalpable tumor Maas M. et al. J ClinOncol2011; 29:4633-4640

  23. T2 – weighted MRI DWI- MRI pre post CRT post CRT patientnoteligibleforwait and see

  24. diagnostic performance of MRI for the prediction of complete response (ypT0) Lambregts D et al. Ann SurgOncol 2011

  25. Pet-CT and clinicalassessment 6 w 12w Perez RO et al. Cancer 2011

  26. Radiationinduced tumor downsizingis time-dependent Dhadda A.S. ClinicalOncology2009; 21:23-31

  27. -S Radio-chemotherapy restingperiod Improvinglocalcontrol in rectalcancer -S Radio-chemotherapy restingperiod -S Radio-chemotherapy restingperiod chemotherapy restingperiod HigherradiationdoseIncreasing interval to surgery EffectiveradiationsensitizationNeoadjuvantchemotherapy

  28. Increasing the interval ? Tulchinsky H et al. SurgOncol2008;15:2661-2667

  29. Retrospective cohort analysis :length of interval and cPR and DFS(Leuven rectalcancer database) Interval (days) ≤ 7 weeks : median 44.0 d n=201 ypT0N0 : 16% > 7 weeks : median 54.0 d n=155 ypT0N0 : 28% (p=0.006) AcceptedAnn SurgOncol2012

  30. Additionalchemotherapyduringrestingperiod Habr-Gama A. Dis Colon Rectum 2009;52(12):1927-1934

  31. pCR Advancedrectalcancer: nonrandomizedphase II prospective trialn=144 -S 18% Radio-chemotherapy restingperiod -S 25% p=0.0217 Radio-chemotherapy mFOLFOX6 Garcia-Anguilar J. Ann Surg2011; 254:97-102

  32. Timing of tumor assessmentat 12 w foreveryone ? Prediction? bad good Perez RO et al. Int J RadiationOncolBiolPhys2012

  33. multimodal defined complete clinical response “wait and see” TAE/TEM (full-thicknesslocalexcision) earlyfailures sustainedcCR ypT0 yp≥T1 late failures delayedradicalsurgery stringent and prolonged FU completionsurgery (after 8 weeks)

  34. Completionradicalafter TAE/TEM does notcompromiseoncologicalresults safe at 6-8 weeks (adequate scar) Mayo data Stage –matched cohort (n=52) Completionradical = primary RR Mainz data CompletionradicalforpT2 = primary RR Hahnloser D, DCR 2005 ; Borschitz T, DCR 2007

  35. Conclusion non-operativetreatmentnotacceptedparadigmyet (butappealing) multimodal-defined cCR improves accuracy patientsshouldbeenrolled in prospectiveregistries Europeannetworkforwatchfulwaiting Kfe.onk@slb.regionsyddanmark.dk longer follow-up needed (>5 yrs.)

More Related